Nothing said here yet.
to join the conversation.
Amneal Pharmaceuticals has seen a strong share price story in recent years, and that raises a straightforward question for you as an investor.
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amneal Pharmaceuticals (AMRX) is back in focus after commentary highlighting slowing sales growth, softer earnings per share trends, and weaker returns on capital that point to execution challenges inside the business.
The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion.
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 12.5% in the afternoon session after the company announced that the U.S. Food and Drug Administration approved its generic lanreotide injection for immediate launch.
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
What a time it’s been for Amneal. In the past six months alone, the company’s stock price has increased by a massive 47.7%, reaching $18.31 per share.
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.